week 3 Flashcards
what does uterine cancer develop from
the endometrium
most common type of uterine neoplasia
adenocarcinoma
risk factors for uterine neoplasia
PCOS
late menopause/early menarche
low parity/nulliparous
obesity
oestrogen only HRT
tamoxifen
genetics- lynch
presentation of uterine neoplasia
abnormal PV bleeding
post menopausal bleeding: endometrial carcinoma until proven otherwise
PV discharge
pain/weight loss
first line investigation for endometrial cancer
TVUS
- measure endometrial thickness (thickness <4mm is reassuring)
investigations for endometrial cancer
TVUS
endometrial biopsy/dilation and curettage
- performed to obtain a tissue sample for histology
hysteroscopy
- allows visualisation of endometrium
histological variation of endometrial carcinoma
purely glandular
areas of squamous differentiation
papillary
clear cell pattern
spread of endometrial carcinoma
usually spreads to myometrium and cervix
but can spread to blood and lymph too
two types of endometrial cancer
type I (endometrioid): most common
type II (serous and clear cell)
what is type I endometrial cancer
endometrioid
- usually diagnosed shortly after menopause
- oestrogen dependent
precursor lesion= atypical hyperplasia
PTEN, KRAS, PIK3CA mutations
Microsatellite instability – germline mutation of mismatch repair genes (Lynch
syndrome)
what is type II endometrial cancer
serous and clear cell
- older women usually
- poorer prognosis
- not associated with unopposed oestrogen
- TP53 mutation
precursor lesion= serous endometrial intraepithelial carcinoma
spreads fallopian tubes
endometrial sarcoma
rare
arise from endometrial stroma and locally aggressive
metastasizes early
staging used for endometrial carcinoma
figo staging
management of endometrial carcinoma
surgery is the principles treatment
- total hysterectomy and bilateral salpingo-oophorectomy + peritoneal washings
radiotherapy
chemotherapy
smooth muscle tumours of the myometrium
leiomyoma
leiomyosarcoma
leiomyoma
common
menorrhagia and infertility
(fibroid)
leiomyosarcoma
rare and poor prognosis
women > 50
peak age of ovarian cancers
75 years